This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;
The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;
The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis
Those who may be allergic to VC005, similar drugs or their excipients.
Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.
Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.